Novartis falls 4% on MS drug concerns
BOSTON (MarketWatch) -- Shares of Swiss drug maker Novartis AG /quotes/zigman/171707/quotes/nls/nvs NVS +0.82% fell 4% early Friday on reports that European regulators were looking into the cardiovascular safety of its recently approved multiple sclerosis treatment Gilenya. Shares of Biogen Idec /quotes/zigman/91573/quotes/nls/biib BIIB +0.01% , which is developing a rival product, were up 1%.
BOSTON (MarketWatch) -- Shares of Swiss drug maker Novartis AG /quotes/zigman/171707/quotes/nls/nvs NVS +0.82% fell 4% early Friday on reports that European regulators were looking into the cardiovascular safety of its recently approved multiple sclerosis treatment Gilenya. Shares of Biogen Idec /quotes/zigman/91573/quotes/nls/biib BIIB +0.01% , which is developing a rival product, were up 1%.